Welcome to our dedicated page for REVITALIST LIFESTYLE WLNS news (Ticker: RVLWF), a resource for investors and traders seeking the latest updates and insights on REVITALIST LIFESTYLE WLNS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REVITALIST LIFESTYLE WLNS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REVITALIST LIFESTYLE WLNS's position in the market.
Revitalist Lifestyle and Wellness Ltd. (OTCQB: RVLWF) announced a non-brokered private placement to issue up to 85,000,000 units at $0.02 per unit, generating gross proceeds of $1,700,000. Each unit consists of one common share and one purchase warrant, exercisable at $0.05 for two years. The offering may close in multiple tranches and proceeds will support company operations and working capital. All securities are subject to a four-month hold period. Revitalist is a leader in the psychedelic wellness space with a presence across 28 states.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) announces the appointment of Paul Auchterlonie as Chief Operating Officer, bringing over 30 years of experience in behavioral health. His leadership aims to enhance the company's strategic response to current mental health demands. Revitalist has also entered into an Exclusive Provider Organization agreement with CoreChoice, which will develop a tailored network for servicing insurance carriers and employer groups. This partnership initiates a payment restructuring approach planned for 2023 to improve care accessibility in the mental health sector.
Benzinga has announced the addition of six influential members to its Psychedelics Advisory Council, enhancing its commitment to the psychedelics industry's growth. The new members include
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has successfully closed a non-brokered private placement, issuing 11,900,000 units at $0.05 each. This funding will expand its telemedicine platform across 28 states, aiming to assist over 50 million individuals with mental health issues, treatment-resistant pain, and palliative care needs. Of the total units, 9,500,000 were issued to settle debts totaling $475,000. The company plans to utilize $120,000 for general working capital and launching its physician-led telemedicine services.
CEO Kathryn Walker emphasizes the urgency in addressing the escalating mental health crisis through increased access to necessary care.
Revitalist Lifestyle and Wellness Ltd. has announced its collaboration with Awakn's Prof. David Nutt to host a webinar on ketamine-assisted therapy for Veterans with addictions. Scheduled for January 12, 2023, at 11:30 AM ET, the session aims to enhance awareness and access to treatment options for the 1.1 million veterans facing substance disorders, notably alcohol abuse. Revitalist will start treating Alcohol Use Disorder at its Chattanooga, Tennessee location, utilizing Awakn's 'Kare' methodology, which achieved an 86% abstinence rate in clinical trials.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) announced a joint venture with WAKE Network, Inc. to open psychedelic clinics and retreats focused on personalized medicine. The joint venture aims to create the world's first vertically integrated psychedelic company, leveraging Wake's psilocybin platform, including Jamaica's largest psilocybin mushroom facility. Revitalist reported a year-to-date revenue of $2.43 million as of June 30, with over 16,000 appointments, achieving a growth rate exceeding 300% year-over-year. Market analysis predicts significant growth in the ketamine treatment market, estimated to reach $3.87 billion by 2027.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has received recognition at the Microdose Awards, with CEO Kathryn Walker being awarded 'Professional Service Practitioner of the Year'. The company continues to expand its services in psychedelic wellness, offering experiential training for healthcare practitioners and launching a nationwide Collaborative Care Network Program. This initiative aims to increase access to ketamine-assisted therapy across over 4,000 clinics in the U.S., addressing gaps in resources for smaller clinics.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has launched two proprietary supplements, Revive+ and Restore+, designed to enhance the outcomes of psychedelic therapy. The supplements, priced at $45 each or $72 for a bundle, include vitamins and adaptogen mushrooms aimed at promoting brain health. The products are available through Revitalist's US clinic network and online. This launch targets the growing market of those who have used psychedelics, potentially benefiting over 93 million Americans, as highlighted by recent data.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has partnered with M-Lend Financial to offer patient financing up to $100,000 for treatments, including ketamine and psychedelic medicine. Clients can finance treatments with monthly payments starting at $42 for a ketamine series. Revitalist aims to increase client appointments to 900 per month, potentially boosting revenues significantly from an initial treatment cost of $3,300.
FAQ
What is the current stock price of REVITALIST LIFESTYLE WLNS (RVLWF)?
What is the market cap of REVITALIST LIFESTYLE WLNS (RVLWF)?
